Sarah Harrington
Primary Care · Tupelo, MSNPI 1720562762
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,787 of the $11,426 with a category attached, or 76.9%. It is spread thinly across 37 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,205 and has fallen 54.6% since, to $1,455 in 2025. Among primary care clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 331 payments — averaging $34.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$2K
- Axonics, Inc.$2K
- Pfizer$1K
- Dendreon Pharmaceuticals LLC$874
- Astellas Pharma US Inc$796
- Bayer$766
- plus $5K from 31 others
What the payments were for
- Speaking & faculty fees$9008%
- Travel & lodging$1,51013%
- Food & beverage$8,78777%
- Education$2292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 17 | $1,675 |
| Axonics, Inc. | 16 | $1,545 |
| Pfizer | 9 | $1,015 |
| Dendreon Pharmaceuticals LLC | 28 | $874 |
| Astellas Pharma US Inc | 42 | $796 |
| Bayer | 36 | $766 |
| Sumitomo Pharma America, Inc. | 37 | $741 |
| Medtronic | 14 | $680 |
| Myriad Genetic Laboratories, Inc. | 15 | $501 |
| Johnson & Johnson | 18 | $392 |
| Merck | 19 | $363 |
| Myovant Sciences Inc. | 19 | $292 |
| Cumberland Pharmaceuticals, Inc. | 4 | $196 |
| 180 Medical, Inc. | 8 | $194 |
| AstraZeneca | 4 | $163 |
| Cook Medical LLC | 1 | $143 |
| Boston Scientific | 3 | $137 |
| Urovant Sciences Inc | 5 | $135 |
| Procept Biorobotics Corporation | 1 | $106 |
| Amgen | 5 | $99 |
| Laborie Medical Technologies Corp. | 1 | $96 |
| Tolmar, Inc. | 4 | $68 |
| Urogen Pharma, Inc. | 3 | $62 |
| Tolmar Pharmaceuticals, Inc. | 3 | $57 |
| Verity Pharmaceuticals Inc. | 3 | $45 |
| AbbVie | 3 | $42 |
| Immunitybio, Inc. | 2 | $39 |
| Convatec Inc. | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Endo Pharmaceuticals Inc. | 2 | $28 |
| Hollister Incorporated | 1 | $19 |
| Endo USA, Inc. | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Novartis | 1 | $17 |
| Halozyme Inc | 1 | $16 |
| Calyxo, Inc. | 1 | $14 |
| Baudax Bio Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift System$1,167
- Axonics$983
- ORGOVYX$900
- INTERSTIM$398
- PROVENGE$262
- Prolaris$249
- Caldolor$150
- Cook$143
- Barrigel$134
- LYNPARZA$122
- Bulkamid$117
- Axonics r-SNM System$112
- AquaBeam Robotic System$106
- Nubeqa$104
- Xofigo$104
How this compares
$11,426 in reported general payments places this provider in the 95th percentile of 80 primary care providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 103 | $1,420,503 |
| ErleadaApalutamide | 79 | $1,164,483 |
| OrgovyxRelugolix | 107 | $273,506 |
| NubeqaDarolutamide | 16 | $201,669 |
| Abiraterone Acetate | 27 | $51,991 |
| MyrbetriqMirabegron | 68 | $51,704 |
| GemtesaVibegron | 53 | $29,868 |
| Estradiol | 41 | $2,938 |
| Tamsulosin Hcl | 220 | $2,590 |
| Methenamine Hippurate | 47 | $2,578 |
| Doxycycline Hyclate | 82 | $1,175 |
| Finasteride | 64 | $853 |
| Tolterodine Tartrate ErTolterodine Tartrate | 17 | $801 |
| Oxybutynin Chloride ErOxybutynin Chloride | 20 | $680 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 39 | $488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $796 | $1,472,207171 claims |
| Johnson & JohnsonErleada | $392 | $1,164,48379 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $741 | $303,375160 claims |
| BayerNubeqa | $766 | $201,66916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 80 primary care providers in Mississippi.
Other primary care in Tupelo
- Mary EatonTupelo$4K
- Tanya SandersonTupelo$3K
- Wanderful PorterTupelo$380
- Alisha McArthur WilkesRidgeland$17K
- Katrina BlackardSouthaven$14K
- Julie HarperNewhebron$10K
- Hannah IvisonJackson$10K
- Irene WilsonSouthaven$4K
- Amanda EllisKosciusko$3K
- Charity MilamSouthaven$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.